A recent study published in Blood Advances suggests that having a low absolute lymphocyte count (ALC) at the time of diagnosis is associated with poorer survival in patients with newly diagnosed multiple myeloma (MM). Conducted at Veterans Affairs medical centers, the study analyzed data from more than 11,000 individuals diagnosed between 2000 ...
Disparities in Multiple Myeloma
Advertisement
Individuals living in lower-income areas experience disproportionately higher rates of late-stage diagnoses and mortality
responding physicians (92%) reported that prior authorization causes treatment delays for their patients
The proportion of myeloma cases linked to BMI and diabetes was higher in Black patients than White patients.
Patients who were Black or female were more likely to refuse treatment for multiple myeloma.
The study looked at disparities in outcomes of infusion with ide-cel or cilta-cel in patients with relapsed or refractory MM.
Significant delays in diagnosing multiple myeloma exist.
Talquetamab is a promising treatment for relapsed multiple myeloma, however, it presents unique side effects.
In MM patients, prescription delays were linked to Black race, older age, inpatient diagnosis, and severe renal impairment.
Advertisement
Expert Interviews
Urban Health Today reports on clinical news and policy updates that directly impact urban health care providers and their patients.
Get research and expert insights straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.